Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
FOG-001 by Fog Pharmaceuticals for Solid Tumor: Likelihood of Approval
FOG-001 is under clinical development by Fog Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
FOG-001 by Fog Pharmaceuticals for Gastric Cancer: Likelihood of Approval
FOG-001 is under clinical development by Fog Pharmaceuticals and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
FOG-001 by Fog Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval
FOG-001 is under clinical development by Fog Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer. According to...
FOG-001 by Fog Pharmaceuticals for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
FOG-001 is under clinical development by Fog Pharmaceuticals and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
FOG-001 by Fog Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval
FOG-001 is under clinical development by Fog Pharmaceuticals and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...